Royalty Pharma
Royalty Pharma

Royalty Pharma

Pharmaceuticals
WebsiteInvestor RelationsSEC
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

$28.4B

Market Cap • 10/23/2026

1996

(30 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,2

P/S

14,6

P/EBITDA

18,7

P/OCF

12,4

P/FCF

12,4

P/E

34

BVPS

15,3

EPS

1,5

Market Cap

Market Cap

28,4B

EV

45,1B

EV/Revenue

17,8

EV/EBITDA

29,7

EV/EBIT

29,8

Payout

Dividend Per Share

0,9

Dividend Yield

1,4%

Buyback Yield

0,9%

Total Yield

2,3%

Dividend Yield 5Y

2,4%

Payout

49%

Retained Earnings

2,5B

Profitability

Gross Margin

100%

EBITDA Margin

59,8%

EBIT Margin

59,6%

Net Margin

53,2%

D&A/EBITDA

0%

R&D/Revenue

9,4%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

14,4%

% PPE

0%

% Goodwill

4,7%

ROE

14%

ROIC

8,3%

Growth

CAGR Revenue 5Y

2,5%

CAGR Op. Income 5Y

-3,4%

CAGR Net Income 5Y

-7,2%

CAGR EPS 5Y

-5,5%

CAGR OCF 5Y

6,9%

Leverage

N.D./EBITDA

5,4

Debt/Equity

0%

Current Ratio

2,8

Quick Ratio

1,3

Interest Coverage

418,7%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium